Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
See our overview of GLP-1, Semaglutide, and Tirzepatide and how our plans work
A 17% Reduction in Overall Cancer Risk A landmark study published in JAMA Oncology (Dai H et al., August 2025), drawing on data from 14 health systems encompassing approximately 20 million patients, found that adults with obesity who were prescribed GLP-1 receptor agonists had a 17% lower risk of developing cancer compared to carefully matched non-users
Since both substances alone are hard on the heart, combining them ups the risk even more
Advanced technique: Some physicians approve splitting to twice-weekly smaller doses during peak side effect weeks (e.g., two 6mg injections instead of one 12mg)
US$ 21.90
US$ 21.53
US$ 24.46
US$ 28.05
